drugset / Trial / NCT05599048
Hyperpolarized 13C MRI as a Biomarker in Advanced Solid Tumors
Phase 1/2
Recruiting
65 enrolled
Robert Bok, MD, PhD
National Cancer Institute (NCI) · collabNational Institute for Biomedical Imaging and Bioengineering (NIBIB) · collabSigma-Aldrich · collab
Non-randomizedSequentialOpen-labelTreatment
Summary
This is a single center prospective imaging study investigating the utility of hyperpolarized 13C-pyruvate +/-13C,15N-Urea/ metabolic MR imaging. The current protocol will serve as a companion imaging biomarker study paired with standard of care (SOC) therapeutics, as well as investigational therapies that participants may be scheduled to receive outside of this protocol.
Timeline
- Start
- 2022-12-15
- Primary completion
- 2027-01-31
- Completion
- 2027-01-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | 13C,15N-Urea | Unknown | — | Intravenous |
| Subject | Hyperpolarized 13C-Pyruvate | Diagnostic / imaging agent | — | Intravenous |